Preventive Effect of Dihydromyricetin against Cisplatin-Induced Nephrotoxicity in Vitro and in Vivo

24Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Nephrotoxicity is a frequent severe side effect of cisplatin chemotherapy, limiting its clinical use despite being one of the most potent chemotherapy drugs. Dihydromyricetin is a highly abundant compound purified from the leaves of Ampelopsis grossedentata. Previous studies have demonstrated the anti-inflammatory and antioxidative effects of Dihydromyricetin both in vitro and in vivo, but little is known about the effects of Dihydromyricetin on cisplatin-induced nephrotoxicity and its underlying mechanisms. In the present study, we investigated its potential renoprotective effect and found that Dihydromyricetin ameliorated the renal functional impairment and structural damage caused by cisplatin. Moreover, Dihydromyricetin markedly attenuated cisplatin-induced oxidative stress, as well as protecting against cisplatin-induced inflammation and apoptotic cell death in mouse kidney tissues. These results collectively highlight the potential of DMY as a rational renoprotective agent against cisplatin.

Cite

CITATION STYLE

APA

Wu, F., Li, Y., Song, H., Zhang, Y., Zhang, Y., Jiang, M., … Tang, D. (2016). Preventive Effect of Dihydromyricetin against Cisplatin-Induced Nephrotoxicity in Vitro and in Vivo. Evidence-Based Complementary and Alternative Medicine, 2016. https://doi.org/10.1155/2016/7937385

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free